[Comment] Prasinezumab: What Have We Learned From PASADENA and PADOVA?

Why It Matters

Demonstrating a disease‑modifying effect in Parkinson's remains a pivotal unmet need; these mixed results reshape expectations for α‑synuclein antibodies and inform the design of future trials.

Key Takeaways

• PASADENA missed primary MDS‑UPDRS endpoint at 52 weeks
• Low‑dose prasinezumab improved motor (Part III) scores versus placebo
• Greater benefit observed in patients already on MAO‑B inhibitors
• Digital biomarkers showed slower progression with prasinezumab
• No difference in DaTSCAN imaging or overall disease trajectory

Pulse Analysis

The hunt for disease‑modifying therapies in Parkinson's disease has centered on α‑synuclein, a protein that aggregates early in the neurodegenerative cascade. Antibody approaches like prasinezumab promise to clear these toxic aggregates, but translating that biology into clinical benefit is fraught with methodological hurdles. Trial designers must balance symptomatic rescue, biomarker selection, and the timing of intervention, especially when patients are already on symptomatic agents such as MAO‑B inhibitors. The PASADENA experience underscores how nuanced these variables are, with the primary MDS‑UPDRS composite failing to show significance while a low‑dose cohort nudged motor scores in the right direction.

A deeper dive into PASADENA’s subgroup data reveals that patients on stable MAO‑B inhibition derived a clearer signal, hinting that background therapy may synergize with α‑synuclein clearance. Moreover, the study leveraged a suite of digital motor assessments—wearable‑derived gait and tremor metrics—that consistently trended toward slower progression in the prasinezumab arms. These digital endpoints, less susceptible to rater bias, could become pivotal secondary outcomes in future Parkinson's trials, offering higher sensitivity to subtle disease‑modifying effects that traditional scales miss.

Looking ahead, the ongoing PADOVA phase‑2b trial will test whether the modest motor gains and digital biomarker trends observed in PASADENA can be replicated in a larger, more diverse cohort. PADOVA also incorporates longitudinal DaTSCAN imaging and fluid biomarkers to triangulate disease trajectory. If prasinezumab can demonstrate consistent benefits across clinical, digital, and biological readouts, it may revive confidence in α‑synuclein immunotherapy and set new standards for trial architecture in neurodegenerative disease. Until then, investors and clinicians will watch closely for any indication that the antibody can move beyond symptomatic relief toward genuine disease modification.